Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

RAINBO NSMP-ORANGE aims to investigate if adjuvant radiotherapy with oral progestin tablets is as effective as radiotherapy with chemotherapy, whilst reducing toxicity and thus improving quality of life, in patients with high-risk NSMP endometrial cancer. Patients will be randomised to radiotherapy with chemotherapy (standard of care), or radiotherapy followed by oral progestin tablets.

Trial Details

NCT ID
NCT07831902
Phase
PHASE3
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • medroxyprogesterone acetate tablets OR megestrol acetate
  • Cisplatin
  • Carboplatin + Paclitaxel
Locations (sample)
  • Bath, United Kingdom|51.3751,-2.36172
  • Cheltenham, United Kingdom|51.90006,-2.07972
  • Leicester, United Kingdom|52.6386,-1.13169
  • London, United Kingdom|51.50853,-0.12574
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Written informed consent and consent for data sharing for the overarching RAINBO programme
  • Histologically confirmed diagnosis of endometrial cancer (EC) of the following histotypes: endometrioid endometrial carcinoma, serous endometrial c…
  • Full molecular classification performed following the diagnostic algorithm described in WHO 2020 (5th Edition, IARC, Lyon, 2020, adapted from Vermi…
  • Hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease afte…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →